CA2588119A1 - Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations - Google Patents
Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations Download PDFInfo
- Publication number
- CA2588119A1 CA2588119A1 CA002588119A CA2588119A CA2588119A1 CA 2588119 A1 CA2588119 A1 CA 2588119A1 CA 002588119 A CA002588119 A CA 002588119A CA 2588119 A CA2588119 A CA 2588119A CA 2588119 A1 CA2588119 A1 CA 2588119A1
- Authority
- CA
- Canada
- Prior art keywords
- healing
- curcumin
- arginine
- composition
- nitroglycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 65
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 39
- 230000036269 ulceration Effects 0.000 title claims abstract description 24
- 230000035876 healing Effects 0.000 title abstract description 31
- 238000000034 method Methods 0.000 title description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 108
- 235000012754 curcumin Nutrition 0.000 claims abstract description 55
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000004148 curcumin Substances 0.000 claims abstract description 54
- 229940109262 curcumin Drugs 0.000 claims abstract description 54
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000004475 Arginine Substances 0.000 claims abstract description 33
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 32
- 239000000006 Nitroglycerin Substances 0.000 claims abstract description 24
- 239000006071 cream Substances 0.000 claims abstract description 10
- 239000003974 emollient agent Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 9
- 239000002480 mineral oil Substances 0.000 claims abstract description 5
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 229940072991 nitro-bid Drugs 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 244000186892 Aloe vera Species 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract description 6
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 6
- 229960003121 arginine Drugs 0.000 abstract description 5
- 239000011787 zinc oxide Substances 0.000 abstract description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 66
- 235000009697 arginine Nutrition 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- 230000029663 wound healing Effects 0.000 description 20
- 231100000397 ulcer Toxicity 0.000 description 14
- 230000004087 circulation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 9
- 229930064664 L-arginine Natural products 0.000 description 9
- 235000014852 L-arginine Nutrition 0.000 description 9
- 230000001010 compromised effect Effects 0.000 description 8
- 238000001804 debridement Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002266 amputation Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000003790 Foot Ulcer Diseases 0.000 description 5
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- MXCVHSXCXPHOLP-UHFFFAOYSA-N 4-oxo-6-propylchromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=CC(CCC)=CC=C21 MXCVHSXCXPHOLP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940124645 emergency medicine Drugs 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005067 remediation Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000010388 wound contraction Effects 0.000 description 2
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 1
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- CVHXQHIJOULCNQ-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate;1-nitropropane-1,2,3-triol Chemical compound OCC(O)C(O)[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O CVHXQHIJOULCNQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- GVYBVPCYMLCVKB-INZIHYEWSA-N COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] Chemical compound COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] GVYBVPCYMLCVKB-INZIHYEWSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000208 phytotoxic Toxicity 0.000 description 1
- 230000000885 phytotoxic effect Effects 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition for treatment of non-healing and slow-healing wounds and ulcerations, and for treating and preventing peripheral neuropathy. The composition is primarily characterized by a combination of nitroglycerin, arginine and curcumin. Preferred embodiments comprise emollient cream, mineral oil, and zinc oxide.
Description
APPLICATION UNDER THE PATENT
COOPERATION TREATY
TITLE: COMPOSITION AND METHOD FOR FACILITATING
THE HEALING OF NON-HEALING AND SLOW-HEALING WOUNDS AND ULCERATIONS
CITATION TO PRIOR APPLICATION
This is a CONTINUATION-IN-PART with respect to U.S.
Application, Serial No. 10/992,636, filed 17 NOVEMBER
2004 (17.11. 2004) and of U.S. Application Serial No.
10/992,623, filed 17 November 2004 (17.11.2004) from both of which priority is claimed under 35 U.S.C. 120 and under provisions of the Paris Convention and of the Patent Cooperation Treaty.
BACKGF2.OUND OF THE INVENTION
1. Field of the Invention The present invention generally relates to an improved composition for treatment of a skin condition.
More specifically, the present invention relates to an improved composition for treatment for common types of skin ulcers, including diabetic, stasis, and decubitus ulcers.
2. . Background Information Wound healing is a highly complex process, involving multiple, co-ordinated interactions of multiple factors and agents. Poor wound healing in diabetics, patients on dialysis, elderly in nursing homes, paralyzed/confined patients in wheel chairs, and patients on hospice is believed to relate to circulatory impairment and its sequlae.
Extensive research leads the present inventors to believe that the most vital elements for successful wound healing are:
1. Nitric Oxide;
2. Endothelial nitric oxide synthase (eNOS/iNOS) (enzyme to make NO from arginine which is in sufficient amounts in properly functioning endothelium and not in diabetic and other compromised patients);
COOPERATION TREATY
TITLE: COMPOSITION AND METHOD FOR FACILITATING
THE HEALING OF NON-HEALING AND SLOW-HEALING WOUNDS AND ULCERATIONS
CITATION TO PRIOR APPLICATION
This is a CONTINUATION-IN-PART with respect to U.S.
Application, Serial No. 10/992,636, filed 17 NOVEMBER
2004 (17.11. 2004) and of U.S. Application Serial No.
10/992,623, filed 17 November 2004 (17.11.2004) from both of which priority is claimed under 35 U.S.C. 120 and under provisions of the Paris Convention and of the Patent Cooperation Treaty.
BACKGF2.OUND OF THE INVENTION
1. Field of the Invention The present invention generally relates to an improved composition for treatment of a skin condition.
More specifically, the present invention relates to an improved composition for treatment for common types of skin ulcers, including diabetic, stasis, and decubitus ulcers.
2. . Background Information Wound healing is a highly complex process, involving multiple, co-ordinated interactions of multiple factors and agents. Poor wound healing in diabetics, patients on dialysis, elderly in nursing homes, paralyzed/confined patients in wheel chairs, and patients on hospice is believed to relate to circulatory impairment and its sequlae.
Extensive research leads the present inventors to believe that the most vital elements for successful wound healing are:
1. Nitric Oxide;
2. Endothelial nitric oxide synthase (eNOS/iNOS) (enzyme to make NO from arginine which is in sufficient amounts in properly functioning endothelium and not in diabetic and other compromised patients);
3. L-arginine (arginine is needed in sufficient amounts in local tissues to be acted on by eNOS to make NO and is.often deficient in diabetic and other compromised populations);
4. Peptide growth factors (especially transforming growth factor beta- TGF-beta);
5. A healthy blood supply (local and systemic);
6. Ability to form new blood supply (angiogenesis);
7. Elimination or absence of microbes causing infection/excessive inflammation;
8. Sufficient macrophages;
9. Normal levels of homocysteine;
In highly compromised populations, such as diabetics, dialysis patients, confined patients, and the chronically ill and elderly, many of these essential factors are missing, or are deleteriously defficient.
The present inventors believe that, when all the above factors are in proper balance, de facto debridement occurs, new cell island matrix flourish, pernicious microbes are minimized, and the three stages of wound healing (a healthy amount of inflammation, proliferation and remodeling) occur efficiently and rapidly.
Various treatments for ulcer-type skin conditions are known in the art, yet none addresses the totality of factors needed to adequately and successfully facilitate healing of that which would be described clinically as "non-healing" or "slow-healing" wounds and ulcerations.
Facts and statistics relating to non-healing and slow-healing wounds and ulcerations, and their underlying origins or propensities, are sobering.
Type II diabetes is one such factor, and is the most common form of the disease, accounting for 90 to 95 percent of all diabetes cases.
Throughout the world, the incidence of Type II
diabetes is nearing epidemic proportions. Examination of current and expected diabetic trends (and the detrimental effects therefrom) is helpful for grasping the tremendous need for the present invention.
By way of example, the Center for Disease Control and Prevention ("CDC") reports an increase in the cases of diagnosed adult diabetes of 49% between 1990 and 2000.
Further, the CDC estimates the diabetes, both diagnosed and undiagnosed, affects approximately seventeen million Americans (or some 6.2% of the U.S. population).
Diabetes is a prevalent disease and an ever-growing domestic and international public health concern. The World Health organization estimates that approximately 150 million people are affected by diabetes; and, these numbers are expected to only get worse (estimated 215 million people affected by 2010; estimated 300 million 5 people affected by 2025). Worldwide, diabetes has a relatively high mortality rate. Diabetes is reportedly among the top five causes of death by disease in most countries, though this may be a conservative ranking.
More likely, diabetes is even more deadly as it is frequently under-reported on death certificates.
Importantly for present purposes - the occurrence of diabetes and skin ulcers and non-healing wounds and ulcerations is directly related. Accordingly, the sharp increase in the number of diabetes cases has led to an increase in the number of people affected by non-healing and slow-healing wounds and ulcerations.
By way of example, diabetics have a fifteen percent chance of developing a foot ulcer during their lifetime.
Of those diabetics that develop foot ulcers, approximately twenty percent will require amputation.
(International J of Pharm Compounding 8(4) July/August 2004, 269). Such amputations are also increasing at an alarming rate. Between 1990 and 2000, the number of amputations resulting from foot ulcers increased by twenty six percent. This trend is expected not only to continue, but to worsen in the coming years. Foot ulcers cause approximately eighty five percent of all diabetic amputation of the lower extremities (Emergency Medicine 36(8) Au 2004, 14-23). The number of such lower extremity amputations (LEA's) now exceeds 100,000 per year!
Recurring foot ulcers, and the amputations that may result, present a continuing problem on a national and global scale. In the event that an ulcer is successfully treated, it is more likely than not that the ulcer will reoccur. Recurrence rates associated with diabetic foot ulcers and resulting LEA's are commonly as high as fifty percent to seventy percent over a period of three to five years.
Those skilled in the art of wound treatment realize that the accepted standard of care is simply not working.
Current medications and modes of treatment all too commonly fail to heal wounds and ulcers in compromised patients, and thereby fail to prevent such complications as infection and gangrene.
Overall, fifty to eighty percent of patients having diabetic foot ulcers will heal within six months-assuming optimal management from a multi-disciplinary team. (Emergency Medicine 36(8) August, 2004, 14-23).
However, all too common complications require hospitalization, painful and expensive surgery, and a prolonged rehabilitation regimen (if rehabilitation is possible at all). With the incidence of ulcer recurrence as high as seventy percent, the healing of one ulcer is often rapidly followed by the development of a new one.
In view of the serious, and often unconquerable consequences of diabetic ulcers alone, and in further view of the need to address non-healing and slow-healing wounds and ulcerations in other compromised patient populations, a great need exists for an improved treatment for non-healing and slow-healing wounds and ulcertations. There is more, however.
Another collateral, or even related condition which afflicts many in the same patient populations as those discussed above with respect to non-healing and slow-healing wounds and ulcerations is that of peripheral neuropathy. Many of the same conditions and circumstances that contribute to non-healing and slow-healing wounds and ulcerations also contribute to, cause, or exacerbate peripheral neuropathy.
Known treatment regimens rely heavily on the use of debridement and washing (clearly involved in the present standard of care). In fact, with only conventional wound treatment regimens available, such steps are necessary, though debridement and washing typically results in scarring, non-closure of the wound, and/or recurrence.
In summary, the present state of would care is woefully deficient, and leaves many patients with' unending pain, loss of extremities, general disability, and even death.
SUMMARY OF THE INVENTION
In view of the above, the general purpose of the present invention, which will be described subsequently in greater detail, is to provide a uniquely efficacious composition and associated method for the treatment of non-healing and slow-healing wounds and ulcerations, as well as peripheral neuropathy, which composition and method are neither anticipated, rendered obvious, suggested, nor even implied by any of the known compositions or methods of treatment, either alone or in any combination thereof.
Therefore, it is an object of the present invention to provide a composition for treatment of non-healing and slow-healing wounds and ulcerations.
It is another object of the present invention to provide a composition and method for treating (or preventing) peripheral neuropathy.
it is another object of the present invention to provide a compound and associated method of use thereof in the treatment of wounds and ulcerations, which composition and use thereof.obviates the need for debridement in wound and ulcer treatment.
It is another object of the present invention to provide a method for treatment of wounds and ulcerations, with particular efficacy for previously non-healing and slow-healing wounds and ulcerations.
It is another object of the present invention to provide a composition and associated method for treatment of non-healing and slow-healing wounds and ulcerations, at least in part, by effecting to an unprecedented level, improvement of circulation at the wound site and associated healing in otherwise non-responsive patients.
5 It is another object of the present invention to provide an improved composition for treatment of non-healing and slow-healing wounds and ulcerations that effects a high degree of pernicious microbe eradication, without requiring debridement or other pre-medication 10 would or ulcer manipulation or alteration.
It is another object of the present invention to provide an improved composition for treatment for non-healing and slow-healing wounds and ulcerations that facilitates peripheral nerve growth and regeneration.
It is yet another object of the present invention to provide an improved composition for treatment for non-healing and slow-healing wounds and ulcerations that effects and utilizes synergistic action of Arginine, Nitroglycerin and Curcumin.
In satisfaction of these and other related objects, the present invention provides a composition and associated treatment method for the treatment of non-healing and slow-healing wounds and ulcerations, as well as the remediation or prevention of peripheral neuropathy associated with impaired circulation. The present invention, by way of a novel composition and associated methods of applying that composition, yields results that simply are not possible with any other known treatments.
The composition of the present invention comprises, principally as active ingredients, nitroglycerin, arginine, and curcumin which have been found by the present inventors to work synergistically to increase the absorption and distribution of each other, as well as to effect an unprecedented therapeutic result. In addition, however, other ingredients (such as the recited zinc and aloe vera constituents) are instrumental in maintaining the medicament on-site for treatment of wounds and ulcerations, such that the optimal therapeutic result is achieved.
A few practical examples, experienced first hand by the present inventors, will reveal the unique benefits of the present invention:
Patient B has had diabetes. for several years, the last two of which he has been confined to a wheel chair.
In highly compromised populations, such as diabetics, dialysis patients, confined patients, and the chronically ill and elderly, many of these essential factors are missing, or are deleteriously defficient.
The present inventors believe that, when all the above factors are in proper balance, de facto debridement occurs, new cell island matrix flourish, pernicious microbes are minimized, and the three stages of wound healing (a healthy amount of inflammation, proliferation and remodeling) occur efficiently and rapidly.
Various treatments for ulcer-type skin conditions are known in the art, yet none addresses the totality of factors needed to adequately and successfully facilitate healing of that which would be described clinically as "non-healing" or "slow-healing" wounds and ulcerations.
Facts and statistics relating to non-healing and slow-healing wounds and ulcerations, and their underlying origins or propensities, are sobering.
Type II diabetes is one such factor, and is the most common form of the disease, accounting for 90 to 95 percent of all diabetes cases.
Throughout the world, the incidence of Type II
diabetes is nearing epidemic proportions. Examination of current and expected diabetic trends (and the detrimental effects therefrom) is helpful for grasping the tremendous need for the present invention.
By way of example, the Center for Disease Control and Prevention ("CDC") reports an increase in the cases of diagnosed adult diabetes of 49% between 1990 and 2000.
Further, the CDC estimates the diabetes, both diagnosed and undiagnosed, affects approximately seventeen million Americans (or some 6.2% of the U.S. population).
Diabetes is a prevalent disease and an ever-growing domestic and international public health concern. The World Health organization estimates that approximately 150 million people are affected by diabetes; and, these numbers are expected to only get worse (estimated 215 million people affected by 2010; estimated 300 million 5 people affected by 2025). Worldwide, diabetes has a relatively high mortality rate. Diabetes is reportedly among the top five causes of death by disease in most countries, though this may be a conservative ranking.
More likely, diabetes is even more deadly as it is frequently under-reported on death certificates.
Importantly for present purposes - the occurrence of diabetes and skin ulcers and non-healing wounds and ulcerations is directly related. Accordingly, the sharp increase in the number of diabetes cases has led to an increase in the number of people affected by non-healing and slow-healing wounds and ulcerations.
By way of example, diabetics have a fifteen percent chance of developing a foot ulcer during their lifetime.
Of those diabetics that develop foot ulcers, approximately twenty percent will require amputation.
(International J of Pharm Compounding 8(4) July/August 2004, 269). Such amputations are also increasing at an alarming rate. Between 1990 and 2000, the number of amputations resulting from foot ulcers increased by twenty six percent. This trend is expected not only to continue, but to worsen in the coming years. Foot ulcers cause approximately eighty five percent of all diabetic amputation of the lower extremities (Emergency Medicine 36(8) Au 2004, 14-23). The number of such lower extremity amputations (LEA's) now exceeds 100,000 per year!
Recurring foot ulcers, and the amputations that may result, present a continuing problem on a national and global scale. In the event that an ulcer is successfully treated, it is more likely than not that the ulcer will reoccur. Recurrence rates associated with diabetic foot ulcers and resulting LEA's are commonly as high as fifty percent to seventy percent over a period of three to five years.
Those skilled in the art of wound treatment realize that the accepted standard of care is simply not working.
Current medications and modes of treatment all too commonly fail to heal wounds and ulcers in compromised patients, and thereby fail to prevent such complications as infection and gangrene.
Overall, fifty to eighty percent of patients having diabetic foot ulcers will heal within six months-assuming optimal management from a multi-disciplinary team. (Emergency Medicine 36(8) August, 2004, 14-23).
However, all too common complications require hospitalization, painful and expensive surgery, and a prolonged rehabilitation regimen (if rehabilitation is possible at all). With the incidence of ulcer recurrence as high as seventy percent, the healing of one ulcer is often rapidly followed by the development of a new one.
In view of the serious, and often unconquerable consequences of diabetic ulcers alone, and in further view of the need to address non-healing and slow-healing wounds and ulcerations in other compromised patient populations, a great need exists for an improved treatment for non-healing and slow-healing wounds and ulcertations. There is more, however.
Another collateral, or even related condition which afflicts many in the same patient populations as those discussed above with respect to non-healing and slow-healing wounds and ulcerations is that of peripheral neuropathy. Many of the same conditions and circumstances that contribute to non-healing and slow-healing wounds and ulcerations also contribute to, cause, or exacerbate peripheral neuropathy.
Known treatment regimens rely heavily on the use of debridement and washing (clearly involved in the present standard of care). In fact, with only conventional wound treatment regimens available, such steps are necessary, though debridement and washing typically results in scarring, non-closure of the wound, and/or recurrence.
In summary, the present state of would care is woefully deficient, and leaves many patients with' unending pain, loss of extremities, general disability, and even death.
SUMMARY OF THE INVENTION
In view of the above, the general purpose of the present invention, which will be described subsequently in greater detail, is to provide a uniquely efficacious composition and associated method for the treatment of non-healing and slow-healing wounds and ulcerations, as well as peripheral neuropathy, which composition and method are neither anticipated, rendered obvious, suggested, nor even implied by any of the known compositions or methods of treatment, either alone or in any combination thereof.
Therefore, it is an object of the present invention to provide a composition for treatment of non-healing and slow-healing wounds and ulcerations.
It is another object of the present invention to provide a composition and method for treating (or preventing) peripheral neuropathy.
it is another object of the present invention to provide a compound and associated method of use thereof in the treatment of wounds and ulcerations, which composition and use thereof.obviates the need for debridement in wound and ulcer treatment.
It is another object of the present invention to provide a method for treatment of wounds and ulcerations, with particular efficacy for previously non-healing and slow-healing wounds and ulcerations.
It is another object of the present invention to provide a composition and associated method for treatment of non-healing and slow-healing wounds and ulcerations, at least in part, by effecting to an unprecedented level, improvement of circulation at the wound site and associated healing in otherwise non-responsive patients.
5 It is another object of the present invention to provide an improved composition for treatment of non-healing and slow-healing wounds and ulcerations that effects a high degree of pernicious microbe eradication, without requiring debridement or other pre-medication 10 would or ulcer manipulation or alteration.
It is another object of the present invention to provide an improved composition for treatment for non-healing and slow-healing wounds and ulcerations that facilitates peripheral nerve growth and regeneration.
It is yet another object of the present invention to provide an improved composition for treatment for non-healing and slow-healing wounds and ulcerations that effects and utilizes synergistic action of Arginine, Nitroglycerin and Curcumin.
In satisfaction of these and other related objects, the present invention provides a composition and associated treatment method for the treatment of non-healing and slow-healing wounds and ulcerations, as well as the remediation or prevention of peripheral neuropathy associated with impaired circulation. The present invention, by way of a novel composition and associated methods of applying that composition, yields results that simply are not possible with any other known treatments.
The composition of the present invention comprises, principally as active ingredients, nitroglycerin, arginine, and curcumin which have been found by the present inventors to work synergistically to increase the absorption and distribution of each other, as well as to effect an unprecedented therapeutic result. In addition, however, other ingredients (such as the recited zinc and aloe vera constituents) are instrumental in maintaining the medicament on-site for treatment of wounds and ulcerations, such that the optimal therapeutic result is achieved.
A few practical examples, experienced first hand by the present inventors, will reveal the unique benefits of the present invention:
Patient B has had diabetes. for several years, the last two of which he has been confined to a wheel chair.
During this past year Patient B has been hospitalized for non-healing pressure ulcers on his buttock region. Every developed ulcer has caused a tremendous amount of pain an suffering. Also, these ulcers have necessitated surgery and costly medical bills. Complication of these ulcers extended to the pelvic bone, which required removal of a portion of the bone. The present composition was applied to the wound one time per day for a period of three days.
By the third day of treatment the wound had decreased in size by approximately twenty five percent. Also, the wound was radically improved, where approximately thirty percent of the wound had been covered with new white granular tissue with obvious healing occurring throughout the entire ulcer. During the next three days, the composition was applied twice daily. After a total of six days of treatment, the original wound was virtually covered with new tissue growth.
Before application of the present composition, Patient F had lost one finger tip to an ulcer and poor circulation. Her entire hand was rigid and swollen.
Before treatment, several of Patient F's fingers were at risk of amputation. After a week of application of the present composition, her hand was soft and mobile, had better circulation, less pain, and a reduction of dark areas marked by poor blood flow. A single lesion had been open to the bone; however, after three days of treatment the lesion went from oozing blood and pus to being completely closed. According to standard treatment protocols, Patient F's lesion would have been reopened for further drainage. However, the present regimens avoids such a necessity.
Patient F has an open scalp lesion of approximately two centimeters in length. After three days of treatment (where the patient continued to wash the wound against Applicant's advise), the lesion had decreased by seventy percent. From the fourth to sixth day, the patient did not wash the wound. By the night of the forth day the lesion has completely closed, By day six, the patient reported a fifty percent reduction in pain such that she could rest her head upon a pillow to sleep.
Patient G had a developing lesion between her buttocks, which appeared to have a monilial infection.
Applicant fear the overlying yeast infection would block entry of the present composition. After two days of treatment, the lesion had improved by some fifty percent.
After a week of treatment, the lesion had completely healed and the patient reported a tremendous decrease in pain and overall discomfort.
In its preferred form (as presently believed, though variations in relative constituency will fall well within the scope of the present invention), the present composition comprises: nitroglycerin (Nitrobid) 2%
ointment, an emollient cream base (PCCA emollient cream formulation), mineral oil (light 65-75 VIS liquid), Curcumin Powder 95% (or a curcumin-containing ingredient, such as a measure of tumeric sufficient to provide the desired measure of curcumin, or even a synthetic curcumin), Aloe Vera (freeze dried 200:1 powder), Zinc Oxide USP, and Arginine (L) USP (HCL powder). This composition is formed as the triturate powders and wet powders are combined with the mineral oil and then thoroughly mixed with emollient cream, QS'ed to the desired volume.
Associated application of the present composition are generally characterized by the topical application.
However, application by injection of the aforementioned composition may be appropriate under certain circumstances. When injected, the medication is typically delivered by syringe in amount depending on the size and depth of the particular lesion. Generally, 5 syringes between 3~ CC and 2CC are sufficient.
The treatment protocol essentially involves leaving the wound alone to heal on its own. That is, the wound is not to be interfered with and use of anti-bacterial or anti-microbial soaps is to be avoided. Debridement and 10 washing of the wound are to be avoided (such has been discovered to promote scarring, non closure, and recurrence of the ulcer). After application of the composition (usually b.i.d.), the wound is typically covered with a tefla pad (or some equivalent) and 15 breathable tape. This allows the wound to remain fairly dry (substantially free of any undue moisture) and open to the surrounding air.
While the characteristics unique to this treatment protocol may at some point, at first appear to be subtle distinctions vis a vis existing prior art, these distinctions self-evidently yield a regimen that is different from any such known in the art and produces unexpected (and previously unachievable) results. For instance, the present method increases blood flow to nerves thereby increasing nerve growth. This expedites the growth of new island cells and allows skin to take root and grow. This appears to be a primary reason for the improved results not seen in any of the known treatment regimen for wound, ulcer or neutopathy consitions.
Further, Applicant has devised a compound that creates effective vasodilation of the underlying-capillary bed in patients with compromised vascular function The present invention eliminates the need for debridement while acting as an agent or substantially eradicating pernicious microbes.
While the synergistic action of the three primary constituents are likely not fully understood or explained at this time, the individual actions of the nitroglycerine, arginine and curcumin, and some aspects of their complimentary actions have been revealed, at least in part, through the present inventors' research and experimentation, Nitroglycerine Nitroglycerin is a nitrate that has been approved by the FDA since 1938 to dilate blood vessels. It is frequently used in the management of angina pectoris. It was first synthesized in 1846 and first used in cardiac therapeutics by physicians since 1879.
Nitroglycerin is a nitric oxide (NO) donor. NO is a small radical that is pivotal for wound healing. Nitrates preferentially dilate blood vessels that are compromised.
Nitroglycerin acts by donating nitric oxide, which relaxes the walls of blood vessels, especially large microvessels.
Non healing wounds especially in diabetic and dialysis patients are notoriously deficient in nitric oxide, as well as the specific enzymes that are involved in nitric oxide local production and in the substrate needed to make NO (the amino acid L-arginine).
Why is NO essential to enhance healing at the wound site?
1. NO improves angiogenesis (Angiogenesis is the process by which new blood vessels form by sprouting from pre-existing vessels);
By the third day of treatment the wound had decreased in size by approximately twenty five percent. Also, the wound was radically improved, where approximately thirty percent of the wound had been covered with new white granular tissue with obvious healing occurring throughout the entire ulcer. During the next three days, the composition was applied twice daily. After a total of six days of treatment, the original wound was virtually covered with new tissue growth.
Before application of the present composition, Patient F had lost one finger tip to an ulcer and poor circulation. Her entire hand was rigid and swollen.
Before treatment, several of Patient F's fingers were at risk of amputation. After a week of application of the present composition, her hand was soft and mobile, had better circulation, less pain, and a reduction of dark areas marked by poor blood flow. A single lesion had been open to the bone; however, after three days of treatment the lesion went from oozing blood and pus to being completely closed. According to standard treatment protocols, Patient F's lesion would have been reopened for further drainage. However, the present regimens avoids such a necessity.
Patient F has an open scalp lesion of approximately two centimeters in length. After three days of treatment (where the patient continued to wash the wound against Applicant's advise), the lesion had decreased by seventy percent. From the fourth to sixth day, the patient did not wash the wound. By the night of the forth day the lesion has completely closed, By day six, the patient reported a fifty percent reduction in pain such that she could rest her head upon a pillow to sleep.
Patient G had a developing lesion between her buttocks, which appeared to have a monilial infection.
Applicant fear the overlying yeast infection would block entry of the present composition. After two days of treatment, the lesion had improved by some fifty percent.
After a week of treatment, the lesion had completely healed and the patient reported a tremendous decrease in pain and overall discomfort.
In its preferred form (as presently believed, though variations in relative constituency will fall well within the scope of the present invention), the present composition comprises: nitroglycerin (Nitrobid) 2%
ointment, an emollient cream base (PCCA emollient cream formulation), mineral oil (light 65-75 VIS liquid), Curcumin Powder 95% (or a curcumin-containing ingredient, such as a measure of tumeric sufficient to provide the desired measure of curcumin, or even a synthetic curcumin), Aloe Vera (freeze dried 200:1 powder), Zinc Oxide USP, and Arginine (L) USP (HCL powder). This composition is formed as the triturate powders and wet powders are combined with the mineral oil and then thoroughly mixed with emollient cream, QS'ed to the desired volume.
Associated application of the present composition are generally characterized by the topical application.
However, application by injection of the aforementioned composition may be appropriate under certain circumstances. When injected, the medication is typically delivered by syringe in amount depending on the size and depth of the particular lesion. Generally, 5 syringes between 3~ CC and 2CC are sufficient.
The treatment protocol essentially involves leaving the wound alone to heal on its own. That is, the wound is not to be interfered with and use of anti-bacterial or anti-microbial soaps is to be avoided. Debridement and 10 washing of the wound are to be avoided (such has been discovered to promote scarring, non closure, and recurrence of the ulcer). After application of the composition (usually b.i.d.), the wound is typically covered with a tefla pad (or some equivalent) and 15 breathable tape. This allows the wound to remain fairly dry (substantially free of any undue moisture) and open to the surrounding air.
While the characteristics unique to this treatment protocol may at some point, at first appear to be subtle distinctions vis a vis existing prior art, these distinctions self-evidently yield a regimen that is different from any such known in the art and produces unexpected (and previously unachievable) results. For instance, the present method increases blood flow to nerves thereby increasing nerve growth. This expedites the growth of new island cells and allows skin to take root and grow. This appears to be a primary reason for the improved results not seen in any of the known treatment regimen for wound, ulcer or neutopathy consitions.
Further, Applicant has devised a compound that creates effective vasodilation of the underlying-capillary bed in patients with compromised vascular function The present invention eliminates the need for debridement while acting as an agent or substantially eradicating pernicious microbes.
While the synergistic action of the three primary constituents are likely not fully understood or explained at this time, the individual actions of the nitroglycerine, arginine and curcumin, and some aspects of their complimentary actions have been revealed, at least in part, through the present inventors' research and experimentation, Nitroglycerine Nitroglycerin is a nitrate that has been approved by the FDA since 1938 to dilate blood vessels. It is frequently used in the management of angina pectoris. It was first synthesized in 1846 and first used in cardiac therapeutics by physicians since 1879.
Nitroglycerin is a nitric oxide (NO) donor. NO is a small radical that is pivotal for wound healing. Nitrates preferentially dilate blood vessels that are compromised.
Nitroglycerin acts by donating nitric oxide, which relaxes the walls of blood vessels, especially large microvessels.
Non healing wounds especially in diabetic and dialysis patients are notoriously deficient in nitric oxide, as well as the specific enzymes that are involved in nitric oxide local production and in the substrate needed to make NO (the amino acid L-arginine).
Why is NO essential to enhance healing at the wound site?
1. NO improves angiogenesis (Angiogenesis is the process by which new blood vessels form by sprouting from pre-existing vessels);
2. NO improves inflammation (healthy inflammation is stage one of wound healing, but then it must be contained. NO does not allow it to intensify);
3. NO promotes cell proliferation;
4. NO enhances matrix deposition;
5. NO helps speeds up remodeling;
6. NO promotes re-eptithlialization (Journal of Investigative Dermatology 1999 Dec;113(6):1090-8) which enhances closure of the wound.
7. NO decrease viscosity by inhibiting platelet aggregation (diabetics and dialysis patients, and often ill and elderly, have excessive clotting of platelets which reduces circulation and healing) (Biological Pharmacology Bulletin 2003 Aug;26(8):1135-43); and 8. Nitrates enhance circulation by increasing red blood cell (erythrocyte) deformability. (International Journal of Clinical Pharmacologic Therapeutics 1998 Jul; 36 (7) :398-402 . ) Therefore, nitroglycerin:
1. Enhances arterial and venous vasodilation/
circulation in large microvessels by donating NO;
3. NO promotes cell proliferation;
4. NO enhances matrix deposition;
5. NO helps speeds up remodeling;
6. NO promotes re-eptithlialization (Journal of Investigative Dermatology 1999 Dec;113(6):1090-8) which enhances closure of the wound.
7. NO decrease viscosity by inhibiting platelet aggregation (diabetics and dialysis patients, and often ill and elderly, have excessive clotting of platelets which reduces circulation and healing) (Biological Pharmacology Bulletin 2003 Aug;26(8):1135-43); and 8. Nitrates enhance circulation by increasing red blood cell (erythrocyte) deformability. (International Journal of Clinical Pharmacologic Therapeutics 1998 Jul; 36 (7) :398-402 . ) Therefore, nitroglycerin:
1. Enhances arterial and venous vasodilation/
circulation in large microvessels by donating NO;
2. Enhances erythrocyte deformability (enhances local circulation);
3. Decreases blood viscosity (improving local circulation); and 4. Improves tissue-oxygen tension (tcp02) (improving circulation and distribution of vital factors to all cells).
In the past, a problem with the use of nitroglycerin is that of headaches occurring in a significant number of patients. Among its many other positive attributes, the present composition, though utilizing nitroglycerin, produces no reported problems with headaches. The present inventors believe that this somehow relates to the presence of curcumin in the composition.
Another feature of nitroglycerine, as revealed through prior investigations for use in wound care, relates to the rapidity of its physiological reactions and ultimate dissipation. This characteristic has greatly limited nitroglycerine's efficacy, when used alone, in wound care, because, to put it plainly, it did not stick around long enough to effect significant would healing.
Further still, prior attempts to use nitroglycerin alone, or in other combinations, revealed some patients' tendency to develop tolerance for the drug, with reduced efficacious results (such as were, to a limited degree, achieved in the first instance).
5 The combination of L-arginine and curcumin with nitroglycerine, as later detailed, provides a therapeutic compound which is more long acting, overcomes the tolerance issue, and also eliminates the headache side effects.
10 Curcumin Curcumin (diferuloylmethane), is a natural product and the most active isolated substance obtained from the plant Curcuma longa (tumeric). Curcumin promotes wound healing by a number of mechanisms.
15 Curcumin significantly accelerates wound healing as it enhances 'expression of TGF-betal and TGF-beta tllrc, both in normal and impaired healing wounds as demonstrated by immunohistochemistry (Biofactors 2002;16(1-2) :29-43) .
3. Decreases blood viscosity (improving local circulation); and 4. Improves tissue-oxygen tension (tcp02) (improving circulation and distribution of vital factors to all cells).
In the past, a problem with the use of nitroglycerin is that of headaches occurring in a significant number of patients. Among its many other positive attributes, the present composition, though utilizing nitroglycerin, produces no reported problems with headaches. The present inventors believe that this somehow relates to the presence of curcumin in the composition.
Another feature of nitroglycerine, as revealed through prior investigations for use in wound care, relates to the rapidity of its physiological reactions and ultimate dissipation. This characteristic has greatly limited nitroglycerine's efficacy, when used alone, in wound care, because, to put it plainly, it did not stick around long enough to effect significant would healing.
Further still, prior attempts to use nitroglycerin alone, or in other combinations, revealed some patients' tendency to develop tolerance for the drug, with reduced efficacious results (such as were, to a limited degree, achieved in the first instance).
5 The combination of L-arginine and curcumin with nitroglycerine, as later detailed, provides a therapeutic compound which is more long acting, overcomes the tolerance issue, and also eliminates the headache side effects.
10 Curcumin Curcumin (diferuloylmethane), is a natural product and the most active isolated substance obtained from the plant Curcuma longa (tumeric). Curcumin promotes wound healing by a number of mechanisms.
15 Curcumin significantly accelerates wound healing as it enhances 'expression of TGF-betal and TGF-beta tllrc, both in normal and impaired healing wounds as demonstrated by immunohistochemistry (Biofactors 2002;16(1-2) :29-43) .
20 Curcumin increases eNos/iNQS within a wound.
As discussed above, NO is a vital factor in wound healing and its production is regulated by inducible nitric oxide synthetase (iNOS) or also called endothelial NO (eNOS) During cutaneous wound repair, iNOS is induced in large quantities, in a normal non compromised patient.
Decreased circulation, poor nutrition, deficient local enzymes, excess sugar within cells, insufficient arginine levels, all decrease the inducibility of iNOS. The presence of a functionally active iNOS is a crucial prerequisite for normal wound reeptithelialization (J
Investigative Dermatology 1999 Dec;113(6):1090-8) Curcumin enhances macrophage production (white blood cells that function to engulfs and kill foreign pathogens and microbes) Curcumin augments vasodilation (Biological Pharmaceutical Bulletin 2003 Aug;26(8):1135-43).
Curcumin demonstrates anti-inflammatory action against mediators of inflammation (Phytomedicine 2005 Jun;12(6-7):445-52. Purified curcumin (More than other curcuminoids in tumeric: demethoxy- or bisdemethoxycurcumin) was found to reduce inflammatory mediators in vitro study.
In experimental animals curcumin has been shown to be anti-diabetic, anti-inflammatory, cytotoxic and have anitoxidant properties (Medical Science Monitor 2005 Jul"11(7):BR228-234).
Curcumin helps fight off pathogens acting as a natural antibiotic.
Curcumin has been found to be effective against bacteria, viruses and fungi.
Curcumin reduced mediators of inflammation from Neisseria gonorrhoeae-induced NF-kappaB signaling.
Curcumin abolished the adherence of bacteria to cells in infection, emphasizing the high potential of curcumin as an anti-microbial compound without cytotoxic side effects (Biological Chemistry 2005 May;386(5):481-90).
Curcumin has antimicrobial action (Journal of Ethnopharmacology 2005 May 13;99(1):147-51 (Letters of Applied Microbiology 2004;39(5):401-6).
Curcumin has antifungal properties - 100% phytotoxic against Lemma minor, Fitoterapia 2005 Mar;76(2):254-7.
Curcumin is anti-inflammatory, antioxidant, anticarcinogenic, antiviral and antiinfectious activities (Critical Reviews for Food Science and Nutrition 2004;44 (2) :97-111) .
Curcumin shows antibacterial, anti-inflammatory, and antineoplastic activity (J Pharmacologic Pharmacology 2000 May:55(5):593-601. Study assessed curcumin in vitro, and with skin absorption of Wistar rats.
Curcumin enhances angiogenesis (Journal of Physiologic Pharmacology 2005 Mar;56 Suppl 1:51-69.
Angiogenesis is a prerequisiste for wound healing.
Curcumin is frequently studied for it's role in enhancing angiogenesis).
Curcumin has been shown in many animal studies to accelerate the repair of excision wounds in mice whole body exposed to various doses of gamma radiation (Journal of Surgical Research 2004 Jul;120(1):127-38.
Radiation disrupts normal response to injury and inhibits normal wound healing and increasing the time of healing. Rats pretreated with curcumin and then exposed to radiation, enhanced wound contraction, decreased healing time, increased synthesis of collagen, hexosamine, DNA, and NO, and improved fibroblast and vascular densities. (Surgical Research 2004 Jul;120(1):127-38)/
Topical curcumin enhances cutaneous wound healing in rats and guinea pigs. Curcumin was effective both orally and topically in diabetic rats and mice. (Wound Repair Regeneration 1998 Mar-Apr'6(2):167-77.
Wounds of animals-treated with curcumin showed earlier re-epithelialization, improved hneovascularization, increased mmigratioh of various cells including dermal myodfibroblasts, fibroblasts, and macrophages into the wound bed, higher collagen content, and increase in transforming growth factor-betal confirmed by in situ hybridization and laser scan cytometry.
Transforming growth factor-betal enhances wound healing and curcumin increases the mRNA transcripts for this growth factor, demonstrating that it enhances the bodies own production of this growth factor, in a natural manner, which may be one mechanism of enhanced wound healing by curcumin (Wound Repair and Regeneration 1998 Mar-Apr; 6 (2) :167-77) .
With respect to safety, curcumin has been used in Phase 1 clinical trials. There was no treatment-related toxicity up to 8,000 mg/day and beyond that the only real problem being the bulky volume was unacceptable to the patients. This was taken orally, and our new drug is via the skin, which reduces systemic exposure significantly.
(Anticancer Research 2001 Jul-Aug;21(4B):2895-900) With respect to the contribution of Arginine to the efficacy of the present composition, NO is generated in 5 the local endothelium through the oxidation of the amino acid L-arginine. This occurs due to the-action of the enzyme eNOS/iNOS.
NO casues vascular smooth muscle to relax causing vasodilation. In addition to being the substrate for 10 eNOS, L-arginie facilitates the dimerization of two identical subunits (Diabetes Care. 2004 Jan;27(1):284-5), forming a homodimer. The enzyme is only active in the dimeric form. Under proper conditions, dimerization occurs rapidly, on a timescale of minutes.
15 Once formed, the dimmer is stable (Journal of Biological Chemistry 2002 277:310200-31010) Arginine Arginine is a substrate to make NO, a particular benefit in use for diabetic and dialysis patients, both 20 who have impaired wound healing, in part, because of a reduction in nitric oxide at wound sites, as is a characteristic of their conditions. The amino acid L-arginine is the only substrate for nitric oxide synthesis.
Treatment in diabetically rendered mice with L-arginine injections significantly increased wound fluid nitrite/nitrate levels. The data demonstrated that the impaired wound healing of diabetic rats can be partially corrected by L-arginine supplementation, and that this effect is accompanied by enhance wound nitric oxide synthesis. Wound Repair Regeneration 2003 May-Jun;11(3):198-203).
NO is a small radical, formed-directly from the amin I o acid L-arginine by three distinct isoforms of the enzyme nitric oxide synthase. The inducible isoform (iNOS) is synthesized in the early phase of wound healing by inflammatory cells, mainly macrophages. Curcumin enhances this production.
During the next proliferative phase, many cells participate in NO synthesis.
NO released through iNOS regulates collagen formation, cell proliferation (new growth of cells to fill in the wound), and wound contraction (for the wound to start growing smaller in the healing process).
Arginine together with NO and curcumin administration promotes these aspects of wound healing.
Arginine regulates dimerization locally, and enhances wound strength and collagen deposition in rodents and humans (Wound Repair Regeneration 2003 May-Jun; 11 (3) :198-203) Synergy between Arginine and Nitroglycerin Arginine dilates small microvessels. The present inventors believe that L-arginine and nitroglycerin compliment each other, in part, because nitroglycerine rapidly dilates relatively larger vessels than optimally does arginine, whereas arginine tends to reside longer at the wound site (or any other tissue site of administration). Thus, nitroglycerine "opens the door"
for arginine to get where it needs to be to effect wound healing, after which, though the nitroglycerine (and its effects) have passed, the arginine remains to effect wound healing.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In the preferred embodiment of the present medicament, and in the medicament upon which an associated method of treatment is based, the primary active ingredients are Nitroglycerin, Arginine, and Curcumin. In this preferred embodiment, the Nitroglycerin is in the form of two percent ointment (NITROBID); the arginine is in the form of Arginine (L) USP, and the Curcumin is in 95% powder form.
The preferred nitroglycerin-arginine-curcumin-based compositions of the present invention may be prepared according to the following disclosure and protocol, with variations appropriate to a desired scale or production as will be apparent to person skilled in the production of pharmaceutical preparations:
A. Constituents of Preferred Embodiment of Composition for remediation of dermal anomalies Ingredients Quantity Nitroglycerin (Nitrobid) 2% ointment 10 GM
Arginine (L) HCL Powder 10 GM
PCCA Emollient cream base 100 GM
Mineral Oil, Light 65-75 VIS liquid 8.33 ML
Curcumin 95% Powder .07 GM
Aloe Vera freeze dried 200:1 powder .2 GM
Zinc Oxide USP 1 GM
Total: 124.5 GM
B. General Mixing Procedure of Preferred Embodiment of the Composition of the present invention:
1. Triturate powders and wet powders with mineral oil and mix thoroughly with emollient cream.
2. Q.S. to desired volume.
The formed composition may then be applied topically to any wound or ulceration (without debridement or washing), usually b.i.d. A treatment period between three and ten days is thought to be sufficient to heal the large majority of treated wounds. Extremely specific dosage is not now believed to be critical, and a "general coverage" of the wound site, generally such as one would apply a sun screen or other lotion, will produce the therapeutic result.
As with any multi-constituent composition, the recited, relative measures of constituent ingredients may be varied to some degree, without noticeably affecting the therapeutic effect of the present composition.
For example, the present .2% Nitroglycerin formulation described above (2mg per gram of medicament) is believed optimal, but.lmg per gram to 50mg per gram is believed still safe (non-toxic) and efficacious, and, even if not optimal, still within the scope of the present invention, when used in combination witharginine and curcumin.
5 Likewise, the present formulation of arginine (0.1%
or 100mg per gram at 10%) is believed variable between lmg per gram up to 1000mg per gram, with retained safety and efficacy. Curcumin is presently shown at an.08o strength (.8mg per gram), and a range of .1 mg per gram 10 up to 50 mg per gram of medicament is believe efficacious and safe (and clearly within the scope of the present invention if efficaciously used as described, with the other active ingredients)..
Furthermore, no evidence presently available would 15 indicate that variations of relative constituency would defeat efficacy or safety. For example, even a 1:2 ratio (in either direction) of nitroglycerine and arginine would not, it is presently believed, defeat the essential therapeutic effects of the present composition, though 20 the recited formulation appears to be roughly a center point of the efficacious mixture.
Therefore, although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limited sense. Various modifications of the disclosed embodiments, as well as alternative embodiments of the inventions will become apparent to persons skilled in the art upon the reference to the description of the invention. It is, therefore, contemplated that the appended claims will cover such modifications that fall within the scope of the invention.
As discussed above, NO is a vital factor in wound healing and its production is regulated by inducible nitric oxide synthetase (iNOS) or also called endothelial NO (eNOS) During cutaneous wound repair, iNOS is induced in large quantities, in a normal non compromised patient.
Decreased circulation, poor nutrition, deficient local enzymes, excess sugar within cells, insufficient arginine levels, all decrease the inducibility of iNOS. The presence of a functionally active iNOS is a crucial prerequisite for normal wound reeptithelialization (J
Investigative Dermatology 1999 Dec;113(6):1090-8) Curcumin enhances macrophage production (white blood cells that function to engulfs and kill foreign pathogens and microbes) Curcumin augments vasodilation (Biological Pharmaceutical Bulletin 2003 Aug;26(8):1135-43).
Curcumin demonstrates anti-inflammatory action against mediators of inflammation (Phytomedicine 2005 Jun;12(6-7):445-52. Purified curcumin (More than other curcuminoids in tumeric: demethoxy- or bisdemethoxycurcumin) was found to reduce inflammatory mediators in vitro study.
In experimental animals curcumin has been shown to be anti-diabetic, anti-inflammatory, cytotoxic and have anitoxidant properties (Medical Science Monitor 2005 Jul"11(7):BR228-234).
Curcumin helps fight off pathogens acting as a natural antibiotic.
Curcumin has been found to be effective against bacteria, viruses and fungi.
Curcumin reduced mediators of inflammation from Neisseria gonorrhoeae-induced NF-kappaB signaling.
Curcumin abolished the adherence of bacteria to cells in infection, emphasizing the high potential of curcumin as an anti-microbial compound without cytotoxic side effects (Biological Chemistry 2005 May;386(5):481-90).
Curcumin has antimicrobial action (Journal of Ethnopharmacology 2005 May 13;99(1):147-51 (Letters of Applied Microbiology 2004;39(5):401-6).
Curcumin has antifungal properties - 100% phytotoxic against Lemma minor, Fitoterapia 2005 Mar;76(2):254-7.
Curcumin is anti-inflammatory, antioxidant, anticarcinogenic, antiviral and antiinfectious activities (Critical Reviews for Food Science and Nutrition 2004;44 (2) :97-111) .
Curcumin shows antibacterial, anti-inflammatory, and antineoplastic activity (J Pharmacologic Pharmacology 2000 May:55(5):593-601. Study assessed curcumin in vitro, and with skin absorption of Wistar rats.
Curcumin enhances angiogenesis (Journal of Physiologic Pharmacology 2005 Mar;56 Suppl 1:51-69.
Angiogenesis is a prerequisiste for wound healing.
Curcumin is frequently studied for it's role in enhancing angiogenesis).
Curcumin has been shown in many animal studies to accelerate the repair of excision wounds in mice whole body exposed to various doses of gamma radiation (Journal of Surgical Research 2004 Jul;120(1):127-38.
Radiation disrupts normal response to injury and inhibits normal wound healing and increasing the time of healing. Rats pretreated with curcumin and then exposed to radiation, enhanced wound contraction, decreased healing time, increased synthesis of collagen, hexosamine, DNA, and NO, and improved fibroblast and vascular densities. (Surgical Research 2004 Jul;120(1):127-38)/
Topical curcumin enhances cutaneous wound healing in rats and guinea pigs. Curcumin was effective both orally and topically in diabetic rats and mice. (Wound Repair Regeneration 1998 Mar-Apr'6(2):167-77.
Wounds of animals-treated with curcumin showed earlier re-epithelialization, improved hneovascularization, increased mmigratioh of various cells including dermal myodfibroblasts, fibroblasts, and macrophages into the wound bed, higher collagen content, and increase in transforming growth factor-betal confirmed by in situ hybridization and laser scan cytometry.
Transforming growth factor-betal enhances wound healing and curcumin increases the mRNA transcripts for this growth factor, demonstrating that it enhances the bodies own production of this growth factor, in a natural manner, which may be one mechanism of enhanced wound healing by curcumin (Wound Repair and Regeneration 1998 Mar-Apr; 6 (2) :167-77) .
With respect to safety, curcumin has been used in Phase 1 clinical trials. There was no treatment-related toxicity up to 8,000 mg/day and beyond that the only real problem being the bulky volume was unacceptable to the patients. This was taken orally, and our new drug is via the skin, which reduces systemic exposure significantly.
(Anticancer Research 2001 Jul-Aug;21(4B):2895-900) With respect to the contribution of Arginine to the efficacy of the present composition, NO is generated in 5 the local endothelium through the oxidation of the amino acid L-arginine. This occurs due to the-action of the enzyme eNOS/iNOS.
NO casues vascular smooth muscle to relax causing vasodilation. In addition to being the substrate for 10 eNOS, L-arginie facilitates the dimerization of two identical subunits (Diabetes Care. 2004 Jan;27(1):284-5), forming a homodimer. The enzyme is only active in the dimeric form. Under proper conditions, dimerization occurs rapidly, on a timescale of minutes.
15 Once formed, the dimmer is stable (Journal of Biological Chemistry 2002 277:310200-31010) Arginine Arginine is a substrate to make NO, a particular benefit in use for diabetic and dialysis patients, both 20 who have impaired wound healing, in part, because of a reduction in nitric oxide at wound sites, as is a characteristic of their conditions. The amino acid L-arginine is the only substrate for nitric oxide synthesis.
Treatment in diabetically rendered mice with L-arginine injections significantly increased wound fluid nitrite/nitrate levels. The data demonstrated that the impaired wound healing of diabetic rats can be partially corrected by L-arginine supplementation, and that this effect is accompanied by enhance wound nitric oxide synthesis. Wound Repair Regeneration 2003 May-Jun;11(3):198-203).
NO is a small radical, formed-directly from the amin I o acid L-arginine by three distinct isoforms of the enzyme nitric oxide synthase. The inducible isoform (iNOS) is synthesized in the early phase of wound healing by inflammatory cells, mainly macrophages. Curcumin enhances this production.
During the next proliferative phase, many cells participate in NO synthesis.
NO released through iNOS regulates collagen formation, cell proliferation (new growth of cells to fill in the wound), and wound contraction (for the wound to start growing smaller in the healing process).
Arginine together with NO and curcumin administration promotes these aspects of wound healing.
Arginine regulates dimerization locally, and enhances wound strength and collagen deposition in rodents and humans (Wound Repair Regeneration 2003 May-Jun; 11 (3) :198-203) Synergy between Arginine and Nitroglycerin Arginine dilates small microvessels. The present inventors believe that L-arginine and nitroglycerin compliment each other, in part, because nitroglycerine rapidly dilates relatively larger vessels than optimally does arginine, whereas arginine tends to reside longer at the wound site (or any other tissue site of administration). Thus, nitroglycerine "opens the door"
for arginine to get where it needs to be to effect wound healing, after which, though the nitroglycerine (and its effects) have passed, the arginine remains to effect wound healing.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In the preferred embodiment of the present medicament, and in the medicament upon which an associated method of treatment is based, the primary active ingredients are Nitroglycerin, Arginine, and Curcumin. In this preferred embodiment, the Nitroglycerin is in the form of two percent ointment (NITROBID); the arginine is in the form of Arginine (L) USP, and the Curcumin is in 95% powder form.
The preferred nitroglycerin-arginine-curcumin-based compositions of the present invention may be prepared according to the following disclosure and protocol, with variations appropriate to a desired scale or production as will be apparent to person skilled in the production of pharmaceutical preparations:
A. Constituents of Preferred Embodiment of Composition for remediation of dermal anomalies Ingredients Quantity Nitroglycerin (Nitrobid) 2% ointment 10 GM
Arginine (L) HCL Powder 10 GM
PCCA Emollient cream base 100 GM
Mineral Oil, Light 65-75 VIS liquid 8.33 ML
Curcumin 95% Powder .07 GM
Aloe Vera freeze dried 200:1 powder .2 GM
Zinc Oxide USP 1 GM
Total: 124.5 GM
B. General Mixing Procedure of Preferred Embodiment of the Composition of the present invention:
1. Triturate powders and wet powders with mineral oil and mix thoroughly with emollient cream.
2. Q.S. to desired volume.
The formed composition may then be applied topically to any wound or ulceration (without debridement or washing), usually b.i.d. A treatment period between three and ten days is thought to be sufficient to heal the large majority of treated wounds. Extremely specific dosage is not now believed to be critical, and a "general coverage" of the wound site, generally such as one would apply a sun screen or other lotion, will produce the therapeutic result.
As with any multi-constituent composition, the recited, relative measures of constituent ingredients may be varied to some degree, without noticeably affecting the therapeutic effect of the present composition.
For example, the present .2% Nitroglycerin formulation described above (2mg per gram of medicament) is believed optimal, but.lmg per gram to 50mg per gram is believed still safe (non-toxic) and efficacious, and, even if not optimal, still within the scope of the present invention, when used in combination witharginine and curcumin.
5 Likewise, the present formulation of arginine (0.1%
or 100mg per gram at 10%) is believed variable between lmg per gram up to 1000mg per gram, with retained safety and efficacy. Curcumin is presently shown at an.08o strength (.8mg per gram), and a range of .1 mg per gram 10 up to 50 mg per gram of medicament is believe efficacious and safe (and clearly within the scope of the present invention if efficaciously used as described, with the other active ingredients)..
Furthermore, no evidence presently available would 15 indicate that variations of relative constituency would defeat efficacy or safety. For example, even a 1:2 ratio (in either direction) of nitroglycerine and arginine would not, it is presently believed, defeat the essential therapeutic effects of the present composition, though 20 the recited formulation appears to be roughly a center point of the efficacious mixture.
Therefore, although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limited sense. Various modifications of the disclosed embodiments, as well as alternative embodiments of the inventions will become apparent to persons skilled in the art upon the reference to the description of the invention. It is, therefore, contemplated that the appended claims will cover such modifications that fall within the scope of the invention.
Claims (8)
1. A topical, medicinal composition comprising:
nitroglycerin; and arginine.
nitroglycerin; and arginine.
2. A topical, medicinal composition comprising:
nitroglycerin;
arginine; and curcumin.
nitroglycerin;
arginine; and curcumin.
3. A topical viscous medicament for topical application to wounds and ulcerations comprising:
nitroglycerin;
arginine; and curcumin;
said nitroglycerin, arginine; and said curcumin being suspended in a viscous carrier medium.
nitroglycerin;
arginine; and curcumin;
said nitroglycerin, arginine; and said curcumin being suspended in a viscous carrier medium.
4. The medicament of Claim 3 wherein said nitroglycerin, arginine; and curcumin are present in approximately ten parts nitroglycerin, approximately ten parts arginine, and approximately 1 part curcumin.
5. The composition of claim 3 wherein said viscous carrier medium comprises an emollient cream and a zinc-containing ingredient.
6. The composition of claim 3 wherein said viscous carrier medium comprises an emollient cream and a quantum of mineral oil.
7. A topical medicament for treatment of wounds and ulcerations comprising:
Nitroglycerin (Nitrobid) 2% ointment;
Arginine (L) HCL Powder;
an emollient cream base;
a first measure of an oil;
curcumin powder;
a first measure of aloe vera approximately; and a zinc-based compound.
Nitroglycerin (Nitrobid) 2% ointment;
Arginine (L) HCL Powder;
an emollient cream base;
a first measure of an oil;
curcumin powder;
a first measure of aloe vera approximately; and a zinc-based compound.
8. A topical medicament for treatment of wounds and ulcerations comprising:
Nitroglycerin (Nitrobid) 2% ointment, approximately 20 parts by weight;
Arginine (L) HCL Powder, approximately 20 parts by weight;
an emollient cream base;
a first measure of an oil;
curcumin powder, approximately 2 part by weight;
a first measure of aloe vera approximately 1 part by weight; and a zinc-based compound, approximately 2 part by weight.
Nitroglycerin (Nitrobid) 2% ointment, approximately 20 parts by weight;
Arginine (L) HCL Powder, approximately 20 parts by weight;
an emollient cream base;
a first measure of an oil;
curcumin powder, approximately 2 part by weight;
a first measure of aloe vera approximately 1 part by weight; and a zinc-based compound, approximately 2 part by weight.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/992,636 US20060105027A1 (en) | 2004-11-17 | 2004-11-17 | Method for treating skin ulcers |
US10/992,623 | 2004-11-17 | ||
US10/992,636 | 2004-11-17 | ||
US10/992,623 US7731993B2 (en) | 2004-11-17 | 2004-11-17 | Composition for treating a dermal anomaly |
PCT/US2005/041708 WO2006055726A2 (en) | 2004-11-17 | 2005-11-17 | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2588119A1 true CA2588119A1 (en) | 2006-05-26 |
Family
ID=36407755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002588119A Abandoned CA2588119A1 (en) | 2004-11-17 | 2005-11-17 | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1827466A4 (en) |
JP (1) | JP2008520694A (en) |
AU (1) | AU2005307736A1 (en) |
BR (1) | BRPI0517731A (en) |
CA (1) | CA2588119A1 (en) |
IL (1) | IL183117A0 (en) |
WO (1) | WO2006055726A2 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0665647B2 (en) * | 1985-06-12 | 1994-08-24 | 株式会社三和化学研究所 | Transdermal treatment agent |
US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
US5925376C1 (en) * | 1994-01-10 | 2001-03-20 | Madalene C Y Heng | Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds |
DE69535607T2 (en) * | 1994-05-27 | 2008-07-10 | Strakan International Ltd. | Composition containing nitrogen oxide donors and method for the treatment of anal diseases |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
JP3667027B2 (en) * | 1997-03-06 | 2005-07-06 | 株式会社ノエビア | Topical skin preparation |
EP1059940B1 (en) * | 1998-02-27 | 2010-01-20 | Synchroneuron, LLC | topical compositions comprising an alpha 1-adrenergic blocker FOR TREATING PAINFUL CONDITIONS OF THE ANAL REGION |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US20030104033A1 (en) * | 2001-07-13 | 2003-06-05 | Lai Chon-Si | Enteral formulations |
US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
-
2005
- 2005-11-17 JP JP2007543244A patent/JP2008520694A/en active Pending
- 2005-11-17 WO PCT/US2005/041708 patent/WO2006055726A2/en active Application Filing
- 2005-11-17 CA CA002588119A patent/CA2588119A1/en not_active Abandoned
- 2005-11-17 EP EP05826664A patent/EP1827466A4/en not_active Withdrawn
- 2005-11-17 BR BRPI0517731-6A patent/BRPI0517731A/en not_active IP Right Cessation
- 2005-11-17 AU AU2005307736A patent/AU2005307736A1/en not_active Abandoned
-
2007
- 2007-05-10 IL IL183117A patent/IL183117A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008520694A (en) | 2008-06-19 |
WO2006055726A2 (en) | 2006-05-26 |
EP1827466A2 (en) | 2007-09-05 |
WO2006055726A3 (en) | 2007-03-22 |
AU2005307736A1 (en) | 2006-05-26 |
EP1827466A4 (en) | 2009-11-11 |
BRPI0517731A (en) | 2008-10-21 |
IL183117A0 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
AU2010257466B2 (en) | Epidermal growth factor composition, a process therefor and its application | |
CN112165960A (en) | Composition for treating chronic wounds | |
US8945636B2 (en) | Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care | |
US11058735B2 (en) | Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract | |
AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
JPH09510978A (en) | Starch-metal complex for skin and hair | |
US8492435B2 (en) | Composition for treating a dermal anomaly | |
SK287249B6 (en) | Medicinal products with cicatrizing action comprising biguanide derivatives | |
WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
WO1994005272A1 (en) | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide | |
KR20140104823A (en) | Pharmaceutical Composition for Preventing or Treating Diabetic Wound | |
CA2588119A1 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
WO1994005279A1 (en) | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid | |
US20080045604A1 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
JP2003528147A (en) | Pharmaceutical gel composition | |
EP1397124B1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
Rajashri et al. | Curcuma Longa and Pineapple Extract Paste in the management of Alveolar Osteitis: An Experimental study | |
US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof | |
US20060105027A1 (en) | Method for treating skin ulcers | |
WO2015159206A1 (en) | Copper alloy microparticles for use in the treatment of an external skin lesion | |
US20100189668A1 (en) | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition | |
JPH07118165A (en) | Transcutaneous absorption composition containing calcitonin gene relating peptide | |
CN110251613A (en) | A kind of compound preparation and preparation method thereof for treating hand decortication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20121119 |